- US Patent allowed for rationally designed synthetic Phylomer libraries;
- Broad applications of synthetic Phylomer libraries in therapeutics and diagnostics;
- Patent allowance further secures Phylogica’s ownership of the entire Phylomer peptide class;
- New patent greatly extends life of Phylogica’s core patent estate – out to November 2027;
- Phylogica is already in discussion with prospective partners interested in accessing this technology.
PERTH, AUSTRALIA: October 2nd, 2013 – Phylogica Ltd (ASX:PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces the allowance of its US patent application for synthetic Phylomer libraries. This core patent (designated USSN 11/672,419) covers generic methods of designing synthetic Phylomer peptide libraries based on the identification of parts of natural proteins, which are predicted to form structures independently when isolated from the parent protein from which they are derived. The patent also contains methods for maximising the diversity of such structures represented in the library.
For further information please download PDF below:
